Immunization, Vaccines and Biologicals

Use of MenAfriVac™ (meningitis A vaccine) in a controlled temperature chain (CTC) during campaigns

Share

Publication details

Number of pages: 26; 40; 30
Publication date: 23 August 2013
Languages: English, French
WHO reference number: WHO/IVB/13.04; WHO/IVB/13.05; WHO/IVB/13.06

Downloads

The need to keep vaccines in a 2°C to 8°C cold chain is a constraining factor for many immunization campaigns due to limited storage capacity and/or limited ice pack freezing capacity; supplementary immunization activities planned across sub-Saharan Africa to introduce MenAfriVac™ are a good example. In 2012, the license for the Serum Institute of India’s meningitis A vaccine, MenAfriVac®, was changed based on a thorough review of scientific data by regulatory authorities and the World Health Organization (WHO) to allow for the use of the vaccine for a period of up to 4 days at temperatures of up to 40°C in a controlled temperature chain (CTC). This document provides countries with guidance on when and how to take advantage of this flexibility.

French versions